Intrinsic value of Allscripts Healthcare Solutions - MDRX

Previous Close

$12.75

  Intrinsic Value

premium content

  Rating & Target

premium content

  Value-price divergence*

premium content

Previous close

$12.75

 
Intrinsic value premium content
 
Up/down potential premium content
 
Rating premium content
 
Value-price divergence* premium content

Premium access subscription - $499/yr

please register and log in before paying

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of MDRX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 2.4

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  11.83
  22.80
  21.02
  19.42
  17.98
  16.68
  15.51
  14.46
  13.51
  12.66
  11.90
  11.21
  10.59
  10.03
  9.52
  9.07
  8.66
  8.30
  7.97
  7.67
  7.40
  7.16
  6.95
  6.75
  6.58
  6.42
  6.28
  6.15
  6.04
  5.93
  5.84
Revenue, $m
  1,550
  1,903
  2,303
  2,751
  3,245
  3,787
  4,374
  5,006
  5,683
  6,402
  7,164
  7,967
  8,810
  9,694
  10,617
  11,580
  12,584
  13,628
  14,714
  15,842
  17,016
  18,235
  19,501
  20,818
  22,188
  23,612
  25,094
  26,638
  28,245
  29,921
  31,668
Variable operating expenses, $m
 
  1,523
  1,802
  2,115
  2,460
  2,839
  3,249
  3,691
  4,164
  4,667
  5,199
  5,568
  6,157
  6,775
  7,420
  8,093
  8,794
  9,524
  10,283
  11,072
  11,892
  12,744
  13,629
  14,549
  15,506
  16,502
  17,538
  18,616
  19,740
  20,911
  22,132
Fixed operating expenses, $m
 
  224
  230
  236
  242
  248
  254
  260
  267
  274
  280
  287
  295
  302
  309
  317
  325
  333
  342
  350
  359
  368
  377
  386
  396
  406
  416
  427
  437
  448
  459
Total operating expenses, $m
  1,490
  1,747
  2,032
  2,351
  2,702
  3,087
  3,503
  3,951
  4,431
  4,941
  5,479
  5,855
  6,452
  7,077
  7,729
  8,410
  9,119
  9,857
  10,625
  11,422
  12,251
  13,112
  14,006
  14,935
  15,902
  16,908
  17,954
  19,043
  20,177
  21,359
  22,591
Operating income, $m
  60
  156
  271
  400
  543
  700
  871
  1,055
  1,252
  1,462
  1,685
  2,112
  2,358
  2,617
  2,888
  3,170
  3,464
  3,770
  4,089
  4,421
  4,765
  5,123
  5,495
  5,883
  6,285
  6,704
  7,141
  7,595
  8,068
  8,562
  9,077
EBITDA, $m
  232
  420
  550
  696
  858
  1,035
  1,228
  1,436
  1,659
  1,896
  2,147
  2,412
  2,690
  2,982
  3,288
  3,606
  3,938
  4,284
  4,644
  5,017
  5,406
  5,810
  6,230
  6,667
  7,121
  7,594
  8,086
  8,599
  9,133
  9,689
  10,270
Interest expense (income), $m
  42
  56
  81
  110
  142
  177
  216
  258
  303
  351
  403
  457
  514
  574
  637
  703
  772
  844
  918
  996
  1,076
  1,160
  1,247
  1,338
  1,432
  1,529
  1,631
  1,737
  1,847
  1,962
  2,081
Earnings before tax, $m
  -15
  100
  190
  290
  401
  523
  655
  797
  949
  1,111
  1,282
  1,655
  1,844
  2,043
  2,250
  2,467
  2,692
  2,927
  3,171
  3,425
  3,689
  3,963
  4,248
  4,545
  4,854
  5,175
  5,509
  5,858
  6,221
  6,600
  6,995
Tax expense, $m
  -18
  27
  51
  78
  108
  141
  177
  215
  256
  300
  346
  447
  498
  552
  608
  666
  727
  790
  856
  925
  996
  1,070
  1,147
  1,227
  1,310
  1,397
  1,488
  1,582
  1,680
  1,782
  1,889
Net income, $m
  3
  73
  139
  212
  293
  382
  478
  582
  693
  811
  936
  1,208
  1,346
  1,491
  1,643
  1,801
  1,965
  2,136
  2,315
  2,500
  2,693
  2,893
  3,101
  3,318
  3,543
  3,778
  4,022
  4,276
  4,541
  4,818
  5,106

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  97
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  3,832
  4,587
  5,551
  6,628
  7,820
  9,124
  10,539
  12,063
  13,694
  15,428
  17,263
  19,197
  21,230
  23,358
  25,583
  27,904
  30,322
  32,838
  35,455
  38,175
  41,001
  43,939
  46,991
  50,165
  53,464
  56,897
  60,469
  64,187
  68,061
  72,098
  76,308
Adjusted assets (=assets-cash), $m
  3,735
  4,587
  5,551
  6,628
  7,820
  9,124
  10,539
  12,063
  13,694
  15,428
  17,263
  19,197
  21,230
  23,358
  25,583
  27,904
  30,322
  32,838
  35,455
  38,175
  41,001
  43,939
  46,991
  50,165
  53,464
  56,897
  60,469
  64,187
  68,061
  72,098
  76,308
Revenue / Adjusted assets
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
  0.415
Average production assets, $m
  806
  990
  1,198
  1,430
  1,688
  1,969
  2,274
  2,603
  2,955
  3,329
  3,725
  4,143
  4,581
  5,041
  5,521
  6,022
  6,543
  7,086
  7,651
  8,238
  8,848
  9,482
  10,141
  10,826
  11,538
  12,278
  13,049
  13,852
  14,688
  15,559
  16,467
Working capital, $m
  -63
  -164
  -198
  -237
  -279
  -326
  -376
  -431
  -489
  -551
  -616
  -685
  -758
  -834
  -913
  -996
  -1,082
  -1,172
  -1,265
  -1,362
  -1,463
  -1,568
  -1,677
  -1,790
  -1,908
  -2,031
  -2,158
  -2,291
  -2,429
  -2,573
  -2,723
Total debt, $m
  1,331
  1,891
  2,555
  3,298
  4,119
  5,018
  5,993
  7,043
  8,166
  9,361
  10,625
  11,958
  13,358
  14,825
  16,358
  17,957
  19,623
  21,356
  23,159
  25,033
  26,981
  29,005
  31,108
  33,294
  35,568
  37,933
  40,394
  42,956
  45,625
  48,407
  51,307
Total liabilities, $m
  2,600
  3,160
  3,824
  4,567
  5,388
  6,287
  7,262
  8,312
  9,435
  10,630
  11,894
  13,227
  14,627
  16,094
  17,627
  19,226
  20,892
  22,625
  24,428
  26,302
  28,250
  30,274
  32,377
  34,563
  36,837
  39,202
  41,663
  44,225
  46,894
  49,676
  52,576
Total equity, $m
  1,232
  1,426
  1,726
  2,061
  2,432
  2,838
  3,278
  3,752
  4,259
  4,798
  5,369
  5,970
  6,602
  7,264
  7,956
  8,678
  9,430
  10,213
  11,026
  11,872
  12,751
  13,665
  14,614
  15,601
  16,627
  17,695
  18,806
  19,962
  21,167
  22,423
  23,732
Total liabilities and equity, $m
  3,832
  4,586
  5,550
  6,628
  7,820
  9,125
  10,540
  12,064
  13,694
  15,428
  17,263
  19,197
  21,229
  23,358
  25,583
  27,904
  30,322
  32,838
  35,454
  38,174
  41,001
  43,939
  46,991
  50,164
  53,464
  56,897
  60,469
  64,187
  68,061
  72,099
  76,308
Debt-to-equity ratio
  1.080
  1.330
  1.480
  1.600
  1.690
  1.770
  1.830
  1.880
  1.920
  1.950
  1.980
  2.000
  2.020
  2.040
  2.060
  2.070
  2.080
  2.090
  2.100
  2.110
  2.120
  2.120
  2.130
  2.130
  2.140
  2.140
  2.150
  2.150
  2.160
  2.160
  2.160
Adjusted equity ratio
  0.304
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311
  0.311

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  3
  73
  139
  212
  293
  382
  478
  582
  693
  811
  936
  1,208
  1,346
  1,491
  1,643
  1,801
  1,965
  2,136
  2,315
  2,500
  2,693
  2,893
  3,101
  3,318
  3,543
  3,778
  4,022
  4,276
  4,541
  4,818
  5,106
Depreciation, amort., depletion, $m
  172
  264
  279
  296
  315
  335
  357
  381
  407
  434
  462
  300
  332
  365
  400
  436
  474
  514
  554
  597
  641
  687
  735
  784
  836
  890
  946
  1,004
  1,064
  1,127
  1,193
Funds from operations, $m
  323
  337
  418
  508
  608
  717
  835
  963
  1,099
  1,245
  1,398
  1,508
  1,678
  1,856
  2,043
  2,237
  2,439
  2,650
  2,869
  3,097
  3,334
  3,580
  3,836
  4,102
  4,379
  4,667
  4,967
  5,280
  5,606
  5,945
  6,300
Change in working capital, $m
  54
  -30
  -34
  -38
  -43
  -47
  -51
  -54
  -58
  -62
  -66
  -69
  -73
  -76
  -79
  -83
  -86
  -90
  -93
  -97
  -101
  -105
  -109
  -113
  -118
  -122
  -127
  -133
  -138
  -144
  -150
Cash from operations, $m
  269
  616
  452
  546
  650
  763
  886
  1,017
  1,158
  1,307
  1,464
  1,577
  1,751
  1,932
  2,122
  2,320
  2,526
  2,740
  2,963
  3,194
  3,435
  3,685
  3,945
  4,215
  4,497
  4,790
  5,095
  5,413
  5,744
  6,090
  6,450
Maintenance CAPEX, $m
  0
  -58
  -72
  -87
  -104
  -122
  -143
  -165
  -189
  -214
  -241
  -270
  -300
  -332
  -365
  -400
  -436
  -474
  -514
  -554
  -597
  -641
  -687
  -735
  -784
  -836
  -890
  -946
  -1,004
  -1,064
  -1,127
New CAPEX, $m
  -138
  -184
  -208
  -233
  -257
  -281
  -305
  -329
  -352
  -374
  -396
  -417
  -439
  -459
  -480
  -501
  -522
  -543
  -565
  -587
  -610
  -634
  -659
  -685
  -712
  -741
  -771
  -803
  -836
  -871
  -908
Cash from investing activities, $m
  -1,154
  -242
  -280
  -320
  -361
  -403
  -448
  -494
  -541
  -588
  -637
  -687
  -739
  -791
  -845
  -901
  -958
  -1,017
  -1,079
  -1,141
  -1,207
  -1,275
  -1,346
  -1,420
  -1,496
  -1,577
  -1,661
  -1,749
  -1,840
  -1,935
  -2,035
Free cash flow, $m
  -885
  374
  172
  227
  289
  360
  438
  524
  617
  718
  826
  890
  1,012
  1,141
  1,277
  1,419
  1,568
  1,723
  1,884
  2,053
  2,228
  2,410
  2,599
  2,796
  3,000
  3,213
  3,434
  3,665
  3,904
  4,154
  4,414
Issuance/(repayment) of debt, $m
  660
  587
  664
  743
  821
  899
  975
  1,050
  1,123
  1,195
  1,265
  1,333
  1,400
  1,467
  1,533
  1,599
  1,666
  1,734
  1,803
  1,874
  1,948
  2,024
  2,103
  2,186
  2,273
  2,365
  2,461
  2,562
  2,669
  2,782
  2,900
Issuance/(repurchase) of shares, $m
  212
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  865
  587
  664
  743
  821
  899
  975
  1,050
  1,123
  1,195
  1,265
  1,333
  1,400
  1,467
  1,533
  1,599
  1,666
  1,734
  1,803
  1,874
  1,948
  2,024
  2,103
  2,186
  2,273
  2,365
  2,461
  2,562
  2,669
  2,782
  2,900
Total cash flow (excl. dividends), $m
  -20
  961
  837
  970
  1,110
  1,258
  1,413
  1,574
  1,740
  1,913
  2,091
  2,223
  2,412
  2,608
  2,810
  3,018
  3,233
  3,456
  3,687
  3,927
  4,175
  4,434
  4,702
  4,982
  5,274
  5,578
  5,895
  6,227
  6,573
  6,936
  7,314
Retained Cash Flow (-), $m
  176
  -264
  -300
  -335
  -371
  -406
  -440
  -474
  -507
  -539
  -571
  -602
  -632
  -662
  -692
  -722
  -752
  -783
  -814
  -846
  -879
  -914
  -949
  -987
  -1,026
  -1,067
  -1,111
  -1,157
  -1,205
  -1,256
  -1,309
Prev. year cash balance distribution, $m
 
  70
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  766
  537
  634
  740
  853
  973
  1,100
  1,233
  1,374
  1,520
  1,621
  1,780
  1,946
  2,118
  2,296
  2,481
  2,674
  2,873
  3,081
  3,296
  3,520
  3,753
  3,995
  4,248
  4,511
  4,785
  5,070
  5,369
  5,680
  6,005
Discount rate, %
 
  8.00
  8.40
  8.82
  9.26
  9.72
  10.21
  10.72
  11.26
  11.82
  12.41
  13.03
  13.68
  14.37
  15.09
  15.84
  16.63
  17.46
  18.34
  19.25
  20.22
  21.23
  22.29
  23.40
  24.57
  25.80
  27.09
  28.45
  29.87
  31.36
  32.93
PV of cash for distribution, $m
 
  709
  457
  492
  519
  536
  543
  539
  525
  503
  472
  421
  382
  340
  296
  253
  212
  173
  139
  109
  83
  62
  45
  32
  22
  15
  9
  6
  4
  2
  1
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Allscripts Healthcare Solutions, Inc. provides information technology and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records, connectivity, private cloud hosting, outsourcing, analytics, patient engagement, clinical decision support, and population health management solutions. The company’s Clinical and Financial Solutions segment provides integrated clinical software applications and financial and information solutions, which primarily include EHR-related, and financial and practice management software solutions, as well as related installation, support and maintenance, outsourcing, private cloud hosting, revenue cycle management, training, and electronic claims administration services. Its Population Health segment offers health management and coordinated care solutions that enable hospitals, health systems, accountable care organizations, and other care facilities to connect, transition, analyze, and coordinate care across the entire care community. The company serves physicians, hospitals, governments, health systems, health plans, life-sciences companies, retail clinics, retail pharmacies, pharmacy benefit managers, insurance companies, and employer wellness clinics, as well as post-acute organizations, such as home health and hospice agencies. Allscripts Healthcare Solutions, Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

FINANCIAL RATIOS  of  Allscripts Healthcare Solutions (MDRX)

Valuation Ratios
P/E Ratio 767.2
Price to Sales 1.5
Price to Book 1.9
Price to Tangible Book
Price to Cash Flow 8.6
Price to Free Cash Flow 17.6
Growth Rates
Sales Growth Rate 11.8%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 102.9%
Cap. Spend. - 3 Yr. Gr. Rate 3.5%
Financial Strength
Quick Ratio 4
Current Ratio 0
LT Debt to Equity 105.8%
Total Debt to Equity 108%
Interest Coverage 1
Management Effectiveness
Return On Assets -0.2%
Ret/ On Assets - 3 Yr. Avg. -1.2%
Return On Total Capital 0.1%
Ret/ On T. Cap. - 3 Yr. Avg. -1.2%
Return On Equity 0.2%
Return On Equity - 3 Yr. Avg. -1.7%
Asset Turnover 0.5
Profitability Ratios
Gross Margin 43.3%
Gross Margin - 3 Yr. Avg. 41.6%
EBITDA Margin 12.8%
EBITDA Margin - 3 Yr. Avg. 11.5%
Operating Margin 3.9%
Oper. Margin - 3 Yr. Avg. 1.1%
Pre-Tax Margin -1%
Pre-Tax Margin - 3 Yr. Avg. -1.9%
Net Profit Margin 0.2%
Net Profit Margin - 3 Yr. Avg. -1.6%
Effective Tax Rate 120%
Eff/ Tax Rate - 3 Yr. Avg. 141%
Payout Ratio 0%

MDRX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the MDRX stock intrinsic value calculation we used $1550 million for the last fiscal year's total revenue generated by Allscripts Healthcare Solutions. The default revenue input number comes from 2016 income statement of Allscripts Healthcare Solutions. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our MDRX stock valuation model: a) initial revenue growth rate of 22.8% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 8%, whose default value for MDRX is calculated based on our internal credit rating of Allscripts Healthcare Solutions, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Allscripts Healthcare Solutions.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of MDRX stock the variable cost ratio is equal to 82.3%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $219 million in the base year in the intrinsic value calculation for MDRX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 4.3% for Allscripts Healthcare Solutions.

Corporate tax rate of 27% is the nominal tax rate for Allscripts Healthcare Solutions. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the MDRX stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for MDRX are equal to 52%.

Life of production assets of 13.8 years is the average useful life of capital assets used in Allscripts Healthcare Solutions operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for MDRX is equal to -8.6%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $1232 million for Allscripts Healthcare Solutions - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 184.853 million for Allscripts Healthcare Solutions is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Allscripts Healthcare Solutions at the current share price and the inputted number of shares is $2.4 billion.


Premium access subscription - $499/yr

please register and log in before paying
RELATED COMPANIES Price Int.Val. Rating
CERN Cerner 67.15 prem.  prem.
QSII Quality System 17.24 prem.  prem.
CPSI Computer Progr 32.75 prem.  prem.
UNH UnitedHealth G 185.70 prem.  prem.
STRM Streamline Hea 1.03 prem.  prem.
MTBC Medical Transc 1.53 prem.  prem.
NH NantHealth 4.47 prem.  prem.
MMM 3M 210.62 prem.  prem.
MCK McKesson 166.62 prem.  prem.
ATHN athenahealth 142.93 prem.  prem.

COMPANY NEWS

▶ Allscripts names new director   [May-24-17 04:01PM  GlobeNewswire]
▶ Allscripts to present at upcoming investor events   [May-17-17 08:01AM  GlobeNewswire]
▶ AllScripts reports 1Q loss   [May-04-17 05:01PM  Associated Press]
▶ AllScripts reports 4Q loss   [04:52PM  AP]
▶ [$$] Allscripts Revenue Rises on Netsmart Acquisition   [04:40PM  at The Wall Street Journal]
▶ [$$] Allscripts: Curb Your Enthusiasm   [11:04AM  at Barrons.com]
▶ Allscripts to extend EMR offerings in Australia   [Dec-04-16 04:30PM  GlobeNewswire]
▶ Hedge Funds Arent Crazy About BGC Partners, Inc. (BGCP) Anymore   [Dec-02-16 08:59AM  at Insider Monkey]
▶ Should You Buy Summit Materials Inc (SUM)?   [Dec-01-16 03:46PM  at Insider Monkey]
▶ Allscripts Announces Expanded Share Repurchase Program   [Nov-17-16 04:15PM  GlobeNewswire]
▶ [$$] Allscripts Healthcare Results Miss Expectations   [Nov-03-16 06:16PM  at The Wall Street Journal]
▶ AllScripts reports 3Q loss   [04:41PM  AP]
Stock chart of MDRX Financial statements of MDRX Annual reports of MDRX
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.